BioLargo OTC Stock Executives
| BLGO Stock | USD 0.25 0.01 3.85% |
BioLargo employs about 31 people. The company is managed by 7 executives with a total tenure of roughly 34 years, averaging almost 4.0 years of service per executive, having 4.43 employees per reported executive. Analysis of BioLargo's management performance can provide insight into the firm performance.
| Dennis Calvert Chairman Chairman, CEO and Pres |
| Joseph Provenzano President Executive VP, VP of Operations, Secretary, Director and President of Odor-No-More, Inc |
BioLargo |
BioLargo Management Team Effectiveness
The company has return on total asset (ROA) of (0.6884) % which means that it has lost $0.6884 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.6331) %, meaning that it created substantial loss on money invested by shareholders. BioLargo's management efficiency ratios could be used to measure how well BioLargo manages its routine affairs as well as how well it operates its assets and liabilities.BioLargo Workforce Comparison
BioLargo is rated fourth in number of employees category among its peers. The total workforce of Materials industry is currently estimated at about 1,298. BioLargo holds roughly 31.0 in number of employees claiming about 2.39% of all equities under Materials industry.
The company has Profit Margin (PM) of (1.29) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.16) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.16. BioLargo Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. BioLargo Price Series Summation is a cross summation of BioLargo price series and its benchmark/peer.
BioLargo Notable Stakeholders
A BioLargo stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as BioLargo often face trade-offs trying to please all of them. BioLargo's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting BioLargo's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Dennis Calvert | Chairman, CEO and Pres | Profile | |
| Joseph Provenzano | Executive VP, VP of Operations, Secretary, Director and President of Odor-No-More, Inc | Profile | |
| Kenneth Code | Chief Science Officer and Director | Profile | |
| Richard Smith | Pres Water | Profile | |
| Randall Moore | Science Engineering | Profile | |
| Steven II | Pres Inc | Profile | |
| CFA II | Chief Officer | Profile |
About BioLargo Management Performance
The success or failure of an entity such as BioLargo often depends on how effective the management is. BioLargo management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of BioLargo management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the BioLargo management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
BioLargo, Inc. invents, develops, and commercializes various platform technologies. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California. Biolargo operates under Chemicals classification in the United States and is traded on OTC Exchange. It employs 31 people.
The data published in BioLargo's official financial statements typically reflect BioLargo's business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving BioLargo's quantitative information. For example, before you start analyzing numbers published by BioLargo accountants, it's essential to understand BioLargo's liquidity, profitability, and earnings quality within the context of the Chemicals space in which it operates.
BioLargo Workforce Analysis
Traditionally, organizations such as BioLargo use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare BioLargo within its industry.BioLargo Manpower Efficiency
Return on BioLargo Manpower
| Revenue Per Employee | 81.6K | |
| Revenue Per Executive | 361.6K | |
| Net Loss Per Employee | 228.4K | |
| Net Loss Per Executive | 1M | |
| Working Capital Per Employee | 33.6K | |
| Working Capital Per Executive | 148.9K |
Other Information on Investing in BioLargo OTC Stock
BioLargo financial ratios help investors to determine whether BioLargo OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioLargo with respect to the benefits of owning BioLargo security.